《公司業績》利福中國(02136.HK)半年純利1.91億元人民幣升7.9%
利福中國(02136.HK)公布截至今年6月底止中期業績,營業額6.03億元人民幣(下同),按年跌1.1%。純利1.91億元,按年升7.9%;每股盈利0.13元。不派息。
期內,上海久光的化妝護膚產品銷售額按年急增 21.3%,是眾多產品類別之中最高。而蘇州久光於引進更多時尚配飾、家庭用品及嬰兒產品的高檔國際品牌後,有關產品的銷售額成為推動銷售所得款項增長的主要動力。受有效的營銷及推廣活動帶動,銷售所得款項淨額按年增加1.2%至16.46億元。若扣除於2018年7月結束營業的日式餐廳業務銷售額,銷售所得款項則按年增加3.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.